HIV/AIDS vaccine: Additional Phase IIa data

GeoVax reported additional data from the double-blind, placebo-controlled, U.S. and Peruvian Phase IIa HVTN 205 trial in 299 healthy, uninfected volunteers showing that HIV gp140 IgG antibody titers in

Read the full 292 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE